Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 40 |
| Active Pipeline (Recruiting Now) | 16 (6) |
| Completed vs Stopped Early | 15 / 9 (22.5%) |
| Median Closed Actual Enrollment | 47 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitario Virgen del Rocío | Seville | 12 |
| Hospital Universitario Ramón y Cajal | Madrid | 10 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07195227 | Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer | Phase II | RECRUITING |
| NCT06180356 | Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression | Phase II | RECRUITING |
| NCT06315010 | Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis | Phase II | RECRUITING |
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Phase III | RECRUITING |
| NCT05708235 | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the MedSIR Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.